Metropolis Healthcare reported 16% YoY revenue growth in Q1 FY27, driven by higher patient volumes and better realization. Fastest growing segments were TruHealth Wellness and Specialty. Margins improved, in line with guidance.
Read More
Cipla reported its highest-ever annual revenue of over ₹28,000 crore for FY26. The company's India business grew 9% to ₹12,500 crore. Cipla recommended a final dividend of ₹13 per share.
Read More
Rainbow Children's Medicare achieved its highest-ever annual revenue of ₹1,703.1 crore and PAT of ₹281.5 crore in FY26. The company added 440 beds and plans to add over 2,500 more in the next five years.
Read More
Rainbow Children's Medicare reported a 15.3% rise in Profit After Tax to ₹281.5 crore for FY 2025-26. Revenue grew 11.49% to ₹17,031 crore. The company added 440 beds and plans for 5,000 beds in five years.
Read More
Samsrita Labs plans a capital reduction to clear ₹11.58 crore in accumulated losses. The company is also pivoting to the pet animal healthcare and wellness sector.
Read More
Nureca Limited reported a significant operational turnaround for FY26, posting an operating profit of ₹8.5 crore against a loss last year. The company is also streamlining operations through a subsidiary merger.
Read More
Nureca Limited reported a 34% YoY revenue growth to ₹146.96 crore for FY26, achieving an operating profit of ₹8.5 crore. However, a net loss of ₹6.1 crore in Q4 FY26, attributed to investment fair value changes, and recent CEO/CFO resign...
Read More
Bliss GVS Pharma Ltd has appointed Rahul Adakmol as its new CEO, effective July 15, 2026. The company is separating the CEO and Managing Director roles, with Narsimha Shibroor Kamath continuing as MD. This move aims to support the compan...
Read More
Fermenta Biotech received FSSAI approval for its plant-based Vitamin D3 product, 'VITADEE Green'. This marks a strategic addition to its nutrition portfolio and supports the 'Make in India' initiative.
Read More
Bliss GVS Pharma announced leadership changes with Rahul Adakmol becoming CEO and Santosh Parab joining as Additional Director. The outgoing CEO remains Managing Director, aiming for stability during the transition.
Read More
Cipla announced its 90th Annual General Meeting, revealing a record-breaking FY 2025-26 with consolidated revenue reaching ₹28,000 crore. The company also maintained a strong cash position of ₹11,000 crore and proposed a final dividend o...
Read More
Rubicon Research's Pithampur facility received a US FDA Form 483 with two procedural observations. The company stated these are not data integrity issues and expects no impact on its commercial ramp-up timeline.
Read More
Syngene International has formally announced the resignation of its Managing Director and CEO, Peter Bains, effective June 30, 2026. This follows a prior notification and is part of a planned leadership transition.
Read More
Fortis Healthcare is expanding into Odisha by partnering with Dion Group to operate a new 300-bed multi-specialty hospital in Cuttack. This move aligns with their asset-light expansion strategy.
Read More
Piramal Pharma reported a net loss of ₹326 crore for FY2026 on revenues of ₹8,869 crore. The company cited inventory destocking and softer order inflows as reasons for this transitional year, expecting a rebound in FY2027.
Read More
Piramal Pharma reported a net loss of ₹326 crore for FY2026, a significant shift from a profit in FY2025. The company cited inventory destocking and market challenges as key reasons for the downturn.
Read More
Zydus Lifesciences partners with Apollo Hospitals to launch the Shield™ Multi-Cancer Detection test in India. This diagnostic tool screens for 10 common cancers and marks a strategic expansion for Zydus in oncology.
Read More
Unichem Laboratories reported FY26 turnover of ₹1,412 crore and a net worth of ₹2,627 crore. The company paid Euro 16.75 million for a patent dispute. Three product recalls also occurred in FY26.
Read More
Unichem Laboratories reported a strong consolidated profit of ₹252.84 crore for FY26, a significant jump from the previous year. The company is strategically shifting its R&D to complex generics and has resolved a major EU patent dispute...
Read More
Fortis Malar Hospitals has ceased all operations after a slump sale. For FY26, it reported a profit of ₹4.2 crore from non-operational income. Investors should watch restructuring plans and legal disputes.
Read More